Definium Therapeutics (NASDAQ:DFTX) used a company event to outline its late-stage development plans for DT120, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results